Proteomedix announces commercial launch of Proclarix® in Europe
News 26.02.2020 Zurich-Schlieren, Switzerland, February 26, 2020. Proteomedix, the Swiss cancer diagnostics company, announced today that Proclarix, its blood-based test for prostate cancer diagnosis, has now been made commercially available in Europe. Proclarix combines proprietary biomarkers and a risk score that accurately identifies an individual patient’s risk for clinically significant prostate cancer. The...